LMR Partners’s Keros Therapeutics KROS Stock Holding History

LMR Partners’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,671	Closed	-$213K	–	1421
2024 Q3	$213K	Buy	+3,671	New	+$181K	﹤0.01%	983
2024 Q2	–	Sell	-3,671	Closed	-$243K	–	1210
2024 Q1	$243K	Buy	+3,671	New	+$218K	﹤0.01%	837
2023 Q4	–	Sell	-27,245	Closed	-$869K	–	1058
2023 Q3	$869K	Hold	27,245	–	–	0.01%	506
2023 Q2	$1.09M	Buy	27,245 +3,574	+15%	+$157K	0.01%	408
2023 Q1	$1.01M	Buy	+23,671	New	+$1.2M	0.02%	605

Other funds holding KROS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

LMR Partners's KROS Position: Q4 2024 in Review

LMR Partners sold out of Keros Therapeutics (KROS) in Q4 2024, closing a stake of 3,671 shares — an estimated $213K sold.

LMR Partners first reported a position in KROS in Q1 2023 and held it in 5 quarters. The position peaked at $1.09M in Q2 2023. 161 funds tracked by Wall St. Rank hold KROS as of Q4 2024.

LMR Partners reported no remaining Keros Therapeutics position as of Q4 2024 after selling out during the quarter.
LMR Partners sold 3,671 Keros Therapeutics shares in Q4 2024, an estimated $213K.
LMR Partners first reported a position in Keros Therapeutics in Q1 2023 and held it in 5 quarters.
LMR Partners's Keros Therapeutics position peaked at $1.09M in Q2 2023.
161 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2024.

Based on LMR Partners's 13F filing for Q4 2024, filed 14 Feb 2025.